(

DEPARTMENT OF HEALTH & HUMAN SERVICES

PUBLIC HEALTH SERVICE NATIONAL INSTITUTES OF HEALTH

FOR US POSTAL SERVICE DELIVERY: Office of Laboratory Animal Welfare 6700B Rockledge Drive, Suite 2500, MSC 6910 Bethesda, Maryland 20892-6910 Home Page: http://grants.nih.gov/grants/olaw/olaw.htm FOR EXPRESS MAIL: Office of Laboratory Animal Welfare 6700B Rockledge Drive, Suite 2500 Bethesda, Maryland 20817 <u>Telephone</u>: (301) 496-7163 <u>Facsimile</u>: (301) 480-3387

July 28, 2021

Re: Animal Welfare Assurance A3391-01 [OLAW Case 3L]

Dr. Christopher O'Byrne Vice President and Associate Dean Research Administration & Operations Wake Forest University Medical Center Boulevard Winston-Salem, NC 27157

Dear Dr. O'Byrne,

The Office of Laboratory Animal Welfare (OLAW) acknowledges receipt of your July 22, 2021 letter reporting an instance of noncompliance with the PHS Policy on Humane Care and Use of Laboratory Animals at Wake Forest University (Wake Forest incident number AWC21-009). We received the initial report via a telephone communication on July 8, 2021. According to the information provided, OLAW understands that in a protocol investigating neurobiology in a domestic cat model, two complications arose in separate animals in June 2021: 1) uncontrolled post-procedural pain, and 2) post-procedural infection that resulted in an animal death. These animals were supported by PHS funding. Relevant costs will be paid from a nonfederal source, as appropriate.

A review of this investigator's research records found inadequate documentation in procedural and other research records, which included the failure to provide post-operative analgesia as directed in the protocol. The inadequate documentation included inconsistencies between reported stock solution use and reported dosing in animal care records, failure to document drug administration, the use of drug regimens approved on a different protocol for a similar procedure, and apparent typos that if correct, would have a negative impact on animal care.

In the case of post-procedural pain noted above, the analgesic regimen provided by the researcher was insufficient to relieve pain between doses and required veterinary intervention. The animal fully recovered with good pain control thereafter. The required post-procedural administration of an NSAID drug (analgesic) was not consistently provided, because the researcher wrongly believed it was to be administered only when signs of pain were evident. This constitutes a failure to follow the approved protocol. On one occasion, this lack of adequate analgesia prompted veterinary intervention to relieve pain. Similar deficiencies in record keeping and protocol adherence were found in 15 separate records managed by this researcher. The infection and death were deemed unexpected complications.

Corrective and preventive actions:

- The IACUC Chair directed the immediate removal of the researcher from the approved IACUC protocol. The IACUC acknowledged this decision without dissent at the next convened meeting.
- 2. The researcher was removed from all approved protocols, and for unrelated reasons the researcher is leaving the institution on July 31, 2021, and

- 3. The approved protocols under this principal investigator will undergo monthly, then quarterly, post-approval monitoring for adherence to approved IACUC protocols and good procedural record keeping for the next year to ensure full compliance, and
- 4. Any serious or continuing noncompliance will result in further disciplinary action.

The prompt consideration of this matter by Wake Forest University was consistent with the philosophy of institutional self-regulation. Similarly, the actions taken to resolve the issue and prevent recurrence were appropriate. Please include the animal species in all future final reports. We appreciate being informed of this matter and find no cause for further action by this office.

Sincerely,

Brent C. Morse -S Morse -S Date: 2021.07.29 07:29:35 -04'00'

Brent C. Morse, DVM Director Division of Compliance Oversight Office of Laboratory Animal Welfare

cc: Assistant Director, Animal Care and Use Committee IACUC contact Dr. Robert M. Gibbens, USDA, APHIS, AC

XX Wake Forest* School of Medicine

Clinical and Translational Science Institute

July 22, 2021

Axel V. Wolff, M.S., D.V.M. Director, Division of Compliance Oversight Office of Laboratory Animal Welfare National Institutes of Health RKL1, Suite 1050, MSC 7982 6705 Rockledge Drive Bethesda, MD 20892-7982

Re: Animal Welfare Assurance A3391-01 Wake Forest incident number AWC21-009

Dear Dr. Wolff,

This is an official notification that Wake Forest University identified and resolved a deviation from standard practices, which the Institutional Animal Care and Use Committee (IACUC) determined must be reported to your office.

PHS funding:

The following PHS funds provided support to this project: R01 EY 026919

In accordance with federal expectations, the IACUC forwards information regarding this incident to the appropriate sponsored research office for the review of direct costs associated with the procurement, care, and use of the animal(s) related to this deviation, as needed. Relevant costs will be paid from a nonfederal source, as appropriate.

Incident:

In a protocol investigating neurobiology in an animal model, two complications arose in separate animals in June 2021: 1) uncontrolled post-procedural pain, and 2) post-procedural infection that resulted in an animal death.

The close timing of these events prompted an immediate review of this investigator's research records. The review found inadequate documentation in procedural and other research records, which included the failure to provide post-operative analgesia as directed in the protocol. The inadequate documentation included inconsistencies between reported stock solution use and reported dosing in animal care records, failure to document drug administration, the use of drug regimens approved on a different protocol for a similar procedure, and apparent typos that if correct, would have a negative impact on animal care.

In the case of post-procedural pain noted above (1), the correct dose and timing of analgesia was documented in the medical record, demonstrating the researcher's intent to be compliant with the approved IACUC protocol, but the analgesic regimen was insufficient to relieve pain between doses and required veterinary intervention. The animal fully recovered with good pain control thereafter. However, the review also found that, for a different procedure under the same approved protocol, the required post-procedural administration of an NSAID drug (analgesic) was not consistently provided,

because the researcher wrongly believed it was to be administered only when signs of pain were evident. This constitutes a failure to follow the approved protocol. On one occasion, this lack of adequate analgesia prompted veterinary intervention to relieve pain. Similar deficiencies in record keeping and protocol adherence were found in 15 separate records managed by this researcher. The infection and death (2) were deemed unexpected complications.

Immediate Actions:

On the same day as the initial review, the IACUC Chair directed the immediate removal of the researcher from the approved IACUC protocol. The IACUC acknowledged this decision without dissent at the next convened meeting.

Preliminary Report:

A preliminary report was provided on this issue to your office on July 8, 2021 by phone message to Dr. Morse.

Resolution:

The principal investigator was responsive and engaged in establishing corrective actions, and a subsequent review of research records within the laboratory and independently by IACUC representatives found good record keeping practices by all other laboratory members.

The IACUC determined that these errors were a serious deviation from acceptable record keeping and expected adherence to approved protocols.

The IACUC approved the following actions to resolve this incident:

- 1. The researcher was removed from all approved protocols, and for unrelated reasons the researcher is leaving the institution on July 31, 2021, and
- The approved protocols under this principal investigator will undergo monthly then quarterly
 post-approval monitoring for adherence to approved IACUC protocols and good procedural
 record keeping for the next year to ensure full compliance, and
- 3. Any serious or continuing noncompliance will result in further disciplinary action.

Wake Forest is committed to protecting the welfare of animals used in research and teaching. Please contact me if you have questions or comments regarding any aspect of this incident or its resolution. Sincerely,

(b) (6)

Christopher O'Byrne Vice President & Associate Dean Research Administration & Operations Institutional Official

cc: Dr. James Jordan, Chairperson, Wake Forest University IACUC AAALAC International

Wolff, Axel (NIH/OD) [E]

From: Sent: To: Cc: Subject:	OLAW Division of Compliance Oversight (NIH/OD) Wednesday, July 28, 2021 8:00 AM (b) (6) OLAW Division of Compliance Oversight (NIH/OD) RE: Final Report on AWC21-009	
Thank you for this report. We will send a response soon. Axel Wolff, M.S., D.V.M.		
Deputy Director, OLAW		

 From:
 (b) (6)

 Sent: Tuesday, July 27, 2021 10:07 AM

 To: OLAW Division of Compliance Oversight (NIH/OD) <olawdco@od.nih.gov>

 Cc:
 (b) (6)

 AAALAC International (accredit@AAALAC.org)

<accredit@AAALAC.org> Subject: Final Report on AWC21-009

Please find the final report on the management of the noncompliance incident AWC21-009 that involved the care and use of animals in research or teaching at Wake Forest University (Assurance No. D16-00248 (A3391-01)).

Please contact us with any questions or concerns.

Thank you,

(b) (6)



Initial Report of Noncompliance

By: BCM

Date:	7/8/2021	Time: Voicemail
Name	of Person repor Telephone #: Fax #: Email:	ng: (b) (6) (b) (6)
		Wake Forest Univ
Fund	ing component	IS funded activity?Yes NEI nt contacted (if necessary):?
What l	nappened?	Wake Forest Reference # AWC21-009
During protoc		t was determined that the researchers had failed to adhere to the approved
Pers Date	cies involved: I onnel involved es and times: ? mal deaths: no	
Project	ted plan and scl	dule for correction/prevention (if known):
Under	review. All cur	nt procedures now per approved protocol.
Project	ted submission	OLAW of final report from Institutional Official:

OFFICE USE ONLY Case #_____